IP Library Granted Patent US 9,409,909
Granted Patent B2
US 9,409,909 · App. 14/446,127 · Granted Aug 9, 2016

N-(2-(hetaryl)aryl)arylsulfonamides and N-(2-(hetaryl)hetaryl)arylsulfonamides

Inventors: Trevor T. Charvat (San Jose, CA); Cheng Hu (Menlo Park, CA); Anita Melikian (San Francisco, CA); Aaron Novack (San Jose, CA); Andrew M. K. Pennell (San Francisco, CA); Edward J. Sullivan (San Jose, CA); William D. Thomas (San Jose, CA); Solomon Ungashe (Fremont, CA); Penglie Zhang (Foster City, CA); Jay Powers (Pacific, CA); Sreenivas Punna (Sunnyvale, CA)
Assignee: ChemoCentryx, Inc.
C07D473/00A61K31/404A61K31/415A61K31/4164A61K31/4192A61K31/437A61K31/496A61K31/52A61K31/5377A61K45/06C07D209/08C07D231/12C07D231/14C07D231/16C07D231/56C07D233/61C07D235/06C07D235/08C07D249/06C07D249/18C07D401/04C07D401/14C07D403/06C07D413/04C07D413/14C07D417/04C07D471/04C07D487/04C12N2501/999
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,409,909
App. No.
14/446,127
Granted
Aug 9, 2016
Kind
B2
Abstract

Compounds are provided that act as potent antagonists of the CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.

Claims (79)

1. A compound, salt, or N-oxide of the formula (I):

where Ar 1 is a substituted or unsubstituted C 6 -10 aryl or substituted or unsubstituted 5- to 10-membered heteroaryl; each having 0 to 5 substituents selected from the group consisting of halogen, substituted or unsubstituted C 1-8 alkyl, substituted or unsubstituted C 2-8 alkenyl, substituted or unsubstituted C 2-8 alkynyl, —CN, —NO 2 , ═O, —C(O)R 3 , —CO 2 R 3 , —C(O)NR 3 R 4 , —OR 3 , —OC(O)R 3 , —OC(O)NR 3 R 4 , —NR 5 C(O)R 3 , —NR 5 C(O)NR 3 R 4 , —NR 3 R 4 , —NR 5 CO 2 R 3 , —NR 5 S(O) 2 R 3 , —SR 3 , —S(O)R 3 , —S(O) 2 R 3 , —S(O) 2 NR 3 R 4 , substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl, and substituted or unsubstituted 3- to 10-membered heterocyclyl;

A is N;

X 1 X 2 X 3 are selected from the group consisting of:

N—N═N

N—C(R 6 )═N

N—N═C(R 7 )

N—C(R 6 )═C(R 7 )

C═N—C(R 7 )

C═C(R 6 )—N(R 5 )

R 1 is hydrogen or C 1-8 alkyl;

each R 2 , R 3 , R 4 , R 6 and R 7 , when present, are independently selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C 1-8 alkyl, substituted or unsubstituted C 2-8 alkenyl, substituted or unsubstituted C 2-8 alkynyl, —CN, ═O, —NO 2 , —OR′, —OC(O)R′, —CO 2 R′, —C(O)R′, —C(O)NR″R′, —OC(O)NR″R′, —NR′″C(O)R′, —NR′″C(O)NR″R′, —NR″R′, —NR′″CO 2 R′, —SR′, —S(O)R′, —S(O) 2 R′, —S(O) 2 NR″R′, —NR″S(O) 2 R′, substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl and substituted or unsubstituted 3- to 10-membered heterocyclyl; or

R 2 and R 3 together with the atoms which they substitute form a substituted or unsubstituted 5-, 6-, or 7-membered ring;

each R 5 is independently selected from group consisting of hydrogen, substituted or unsubstituted C 1-8 alkyl, substituted or unsubstituted C 2-8 alkenyl, substituted or unsubstituted C 2-8 alkynyl, —CO 2 R′, —C(O)R′, —C(O)NR″R′, —S(O)R′, —S(O) 2 R′, —S(O) 2 NR″R′, substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl, and substituted or unsubstituted 3- to 10-membered heterocyclyl; and

R′, R″ and R′″ are each independently hydrogen or unsubstituted C 1-4 alkyl; or R′ and R″ together with the atoms which they substitute form a substituted or unsubstituted 5-, 6-, or 7-membered ring.

2. The compound of claim 1 , which is of the formula (II), or a salt thereof:

where R 8 , R 9 , R 10 , R 11 , and R 12 are each independently selected from the group consisting of hydrogen, halogen, C 1-8 alkoxy, C 1-8 alkyl, —CN, or C 1-8 haloalkyl.

3. The compound of claim 2 , which is of the formula (IV), or a salt thereof:

4. The compound of claim 2 , which is of the formula (V), or a salt thereof:

5. A composition comprising a pharmaceutically acceptable carrier and a compound of claim 1 .

6. The compound of claim 2 , which is of the formula (VI), or a salt thereof:

7. The compound of claim 1 , which is of the formula (CCI), or a salt thereof:

where R 1 is a halogen, C 1-8 alkoxy, C 1-8 alkyl, —CN, or C 1-8 haloalkyl;

each R 2 is independently hydrogen, halogen, C 1-8 alkyl, —CN, or C 1-8 haloalkyl;

R 3 is hydrogen or C 1-8 alkyl;

R 4 is halogen or C 1-8 alkyl;

R 5 is hydrogen, halogen or C 1-8 alkyl;

R 6 , R 7 , R 8 and R 9 are each independently selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C 1-8 alkyl, substituted or unsubstituted C 2-8 alkenyl, substituted or unsubstituted C 2-8 alkynyl, —CN, ═O, —NO 2 , —OR′, —OC(O)R′, —C(O)R′, —C(O)NR″R′, —OC(O)NR″R′, —NR′″C(O)R′, —NR′″C(O)NR″R′, —NR″R′, —NR′″CO 2 R′, —SR′, —S(O)R′, —S(O) 2 R′, —S(O) 2 NR″R′, —NR″S(O) 2 R′, substituted or unsubstituted C 6 -10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl and substituted or unsubstituted 3- to 10-membered heterocyclyl; or

R 6 and R 7 together with the atoms which they substitute form a substituted or unsubstituted 5-, 6-, or 7-membered ring;

X 3 is CR 8 or N; and

X 2 is CR 9 or N.

8. The compound of claim 7 , which is of the formula (CCII), or a salt thereof:

9. The compound of claim 7 , which is of the formula of (CCIII), or a salt thereof:

10. The compound of claim 7 , which is of the formula of (CCIV), or a salt thereof:

11. The compound of claim 7 , which is of the formula of (CCV), or a salt thereof:

12. The compound of claim 7 , which is of the formula of (CCVI), or a salt thereof:

13. The compound of claim 1 , which is:

4-tert-butyl-N-(5-chloro-2-(1H-pyrazolo[4,3-b]pyridine-1-yl)pyridine-3-yl)benzenesulfonamide;

4-tert-butyl-N-(5-chloro-2-(5-methyl-1H-pyrazolo[4,3-b]pyridine-1-yl)pyridine-3-yl)benzenesulfonamide;

4-tert-butyl-N-(5-chloro-2-(1H-imidazo[4,5-b]pyridine-1-yl)pyridine-3-yl)benzenesulfonamide; and

4-tert-butyl-N-(5-chloro-2-(3H-imidazo[4,5-b]pyridine-3-yl)pyridine-3-yl)benzenesulfonamide;

N-(2-(5-amino-1H-pyrrolo[3,2-b]pyridin-1-yl)-5-chloropyridin-3-yl)-4-tert-butylbenzenesulfonamide;

N-(2-(1H-[1,2,3]triazolo[4,5-b]pyridin-1-yl)-5-chloropyridin-3-yl)-4-tert-butylbenzenesulfonamide;

ethyl 1-(3-(4-tert-butylphenylsulfonamido)-5-chloropyridin-2-yl)-1H-pyrazole-4-carboxylate;

N-(2-(1H-[1,2,3]triazolo[4,5-b]pyridin-1-yl)-5-methylpyridin-3-yl)-4-tert-butylbenzenesulfonamide;

4-tert-butyl-N-(5-chloro-2-(4-chloro-1H-pyrazol-1-yl)pyridin-3-yl)benzenesulfonamide;

4-tert-butyl-N-(5-chloro-2-(4-methyl-1H-imidazol-1-yl)pyridin-3-yl)benzenesulfonamide;

4-tert-butyl-N-(5-chloro-2-(4-phenyl-1H-imidazol-1-yl)pyridin-3-yl)benzenesulfonamide;

4-tert-butyl-N-(5-chloro-2-(2-methyl-1H-imidazol-1-yl)pyridin-3-yl)benzenesulfonamide;

4-tert-butyl-N-(5-chloro-2-(2-isopropyl-1H-imidazol-1-yl)pyridin-3-yl)benzenesulfonamide;

4-tert-butyl-N-(5-chloro-2-(2-phenyl-1H-imidazol-1-yl)pyridin-3-yl)benzenesulfonamide;

4-tert-butyl-N-(5-chloro-2-(2-ethyl-1H-imidazol-1-yl)pyridin-3-yl)benzenesulfonamide;

4-tert-butyl-N-(5-chloro-2-(1H-indol-1-yl)pyridin-3-yl)benzenesulfonamide;

N-(2-(1H-benzo[d]imidazol-1-yl)-5-chloropyridin-3-yl)-4-tert-butylbenzenesulfonamide;

4-tert-butyl-N-(5-chloro-2-(1H-indazol-1-yl)pyridin-3-yl)benzenesulfonamide;

N-(2-(1H-benzo[d][1,2,3]triazol-1-yl)-5-chloropyridin-3-yl)-4-tert-butylbenzenesulfonamide;

4-tert-butyl-N-(5-chloro-2-(9H-purin-9-yl)pyridin-3-yl)benzenesulfonamide;

4-tert-butyl-N-(5-chloro-2-(2,4-dimethyl-1H-imidazol-1-yl)pyridin-3-yl)benzenesulfonamide;

4-tert-butyl-N-(5-chloro-2-(2-ethyl-4-methyl-1H-imidazol-1-yl)pyridin-3-yl)benzenesulfonamide;

4-tert-butyl-N-(5-chloro-2-(4-(piperidine-1-carbonyl)-1H-pyrazol-1-yl)pyridin-3-yl)benzenesulfonamide;

4-tert-butyl-N-(5-chloro-2-(4-(morpholine-4-carbonyl)-1H-pyrazol-1-yl)pyridin-3-yl)benzenesulfonamide;

4-tert-butyl-N-(5-chloro-2-(4-(pyrrolidine-1-carbonyl)-1H-pyrazol-1-yl)pyridin-3-yl)benzenesulfonamide;

4-tert-butyl-N-(5-chloro-2-(4-(4-methylpiperazine-1-carbonyl)-1H-pyrazol-1-yl)pyridin-3-yl)benzenesulfonamide;

N-(2-(4-(azetidine-1-carbonyl)-1H-pyrazol-1-yl)-5-chloropyridin-3-yl)-4-tert-butylbenzenesulfonamide;

1-(3-(4-tert-butylphenylsulfonamido)-5-chloropyridin-2-yl)-N-isopropyl-N-methyl-1H-pyrazole-4-carboxamide;

4-tert-butyl-N-(5-chloro-2-(4-(4-isopropylpiperazine-1-carbonyl)-1H-pyrazol-1-yl)pyridin-3-yl)benzenesulfonamide;

4-tert-butyl-N-(5-chloro-2-(4-(3-(dimethylamino)pyrrolidine-1-carbonyl)-1H-pyrazol-1-yl)pyridin-3-yl)benzenesulfonamide;

1-(3-(4-tert-butylphenylsulfonamido)-5-chloropyridin-2-yl)-N-(2-(dimethylamino)ethyl)-N-methyl-1H-pyrazole-4-carboxamide;

4-tert-butyl-N-(5-chloro-2-(4-(1,2,3,6-tetrahydropyridine-1-carbonyl)-1H-pyrazol-1-yl)pyridin-3-yl)benzenesulfonamide;

1-(3-(4-tert-butylphenylsulfonamido)-5-chloropyridin-2-yl)-N-methyl-1H-pyrazole-4-carboxamide;

1-(3-(4-tert-butylphenylsulfonamido)-5-chloropyridin-2-yl)-N,N-dimethyl-1H-pyrazole-4-carboxamide;

1-(3-(4-tert-butylphenylsulfonamido)-5-chloropyridin-2-yl)-N,3-dimethyl-1H-pyrazole-4-carboxamide;

1-(3-(4-tert-butylphenylsulfonamido)-5-chloropyridin-2-yl)-N,N,3-trimethyl-1H-pyrazole-4-carboxamide;

1-(3-(4-tert-butylphenylsulfonamido)-5-chloropyridin-2-yl)-1H-pyrazole-4-carboxylic acid;

N-(2-(4-amino-1H-pyrazol-1-yl)-5-chloropyridin-3-yl)-4-tert-butylbenzenesulfonamide;

N-(1-(3-(4-tert-butylphenylsulfonamido)-5-chloropyridin-2-yl)-1H-pyrazol-4-yl)acetamide; and

4-tert-butyl-N-(5-chloro-2-(4-(oxazol-2-yl)-1H-pyrazol-1-yl)pyridin-3-yl)benzenesulfonamide;

or a salt thereof.

14. The composition of claim 5 , further comprising an anti-inflammatory or analgesic agent.

Continuity (7)
Continuation 13462393 · May 2, 2012
Continuation 12832374 · Jul 8, 2010
Continuation 12140593 · Jun 17, 2008
Provisional Application 61046291 · Apr 18, 2008
Provisional Application 60948796 · Jul 10, 2007
Provisional Application 60945849 · Jun 22, 2007
Related Publication 20150018337A1 · Jan 15, 2015